Better Health for All

Niagen Bioscience's core product, Niagen®, a nicotinamide riboside (NR) supplement, has demonstrated significant health benefits. A clinical trial published in Aging Cell showed a ~140% increase in plasma NAD+ levels in Werner Syndrome patients, with improvements in cardiovascular health, skin integrity, and kidney function.

The company's NAD+ approach is supported by over 35 clinical studies, with more than 65% of registered ongoing or completed NR trials using Niagen. Niagen Bioscience is also investigating a potential treatment for Parkinson's Disease with the NOPARK trial (Phase III, 400 participants, 52 weeks), with results expected by the end of 2025. The company's products are health-enhancing supplements, with no evidence of revenue from harmful products. Niagen® and Tru Niagen® undergo 22 internal and third-party tests for potency, safety, and purity, holding ISO/IEC 17025:2017 accreditation and approvals from US-FDA (NDI and GRAS), EFSA, Health Canada, TGA, and the Turkish Ministry of Agriculture. Clinical trials for Werner Syndrome reported no severe adverse events, and mild adverse events were fewer in the Niagen group (7) compared to placebo (12). The NOPARK trial also assesses safety. The company invests significantly in research through its ChromaDex External Research Program (CERP), which has supported over 300 studies at more than 200 institutions in 30+ countries since 2013. Over 90% of Niagen studies are investigator-driven and third-party funded, and the NOPARK trial is randomized, double-blind, and placebo-controlled, indicating strong ethical conduct. Niagen Bioscience also provides healthcare practitioner-specific webinars and modules, demonstrating investment in healthcare education. However, the company's products are generally considered safe for short-term use, but long-term safety is not fully understood, and potential cancer risks are noted, without clear evidence of comprehensive public disclosure of these risks.

Fair Money & Economic Opportunity

The provided articles focus on Niagen Bioscience's research, partnerships, and product offerings related to NAD+ science and dietary supplements.

None of the articles contain any data or information relevant to financial services, lending practices, consumer protection, or any other aspect of the 'Fair Money & Economic Opportunity' value. Therefore, no KPIs can be scored based on the evidence provided.

Fair Trade & Ethical Sourcing

The provided articles do not contain any specific, quantitative data points or verifiable facts related to Niagen Bioscience, Inc.'s fair trade certifications, supplier audit frequency for ethical sourcing, forced or child labor incidents, supply chain traceability, remediation speed for violations, ethical clause coverage in supplier contracts, share of high-risk materials, or supplier diversity spend.

Therefore, no assessment can be made against the 'Fair Trade & Ethical Sourcing' value based on the evidence provided.

Honest & Fair Business

Niagen Bioscience, Inc. has a formal whistleblower policy that includes an ethics hotline for anonymous reporting and encourages reporting without retaliation.

However, there is no evidence provided regarding independent investigation processes for these reports. The company also has an anti-corruption policy that addresses the Foreign Corrupt Practices Act (FCPA), U.S. Embargoes, U.S. Export Controls, and Antiboycott Regulations, emphasizing compliance with international laws and covering bribery/corruption. No information is available regarding the frequency of training or effectiveness metrics for this policy.

Kind to Animals

Tru Niagen products are explicitly stated to be made without animal byproducts.

However, the company's research and preclinical studies consistently utilize animal models. Dr. Charles Brenner has demonstrated the effects of oral nicotinamide riboside (NR) in animal models for conditions such as fatty liver disease, obesity, type 2 diabetes, heart failure, and neurodegeneration. Preclinical studies have also used mouse and hamster models to assess Niagen's therapeutic potential for COVID-19, and mice models for preventing hearing loss. While the specific number of animals used is not quantified, the repeated and varied use of animal models across multiple research areas indicates a significant volume of animal testing. There is no mention of a formal policy to restrict or reduce animal testing, nor are there transparent reduction targets.

Planet-Friendly Business

No specific, concrete data points were found across the provided articles for any of the Planet-Friendly Business KPIs. The articles primarily focus on financial performance, legal proceedings, and regulatory warnings related to product claims. Several articles explicitly state that no data is available for environmental metrics such as emissions, renewable energy, or sustainability targets.

This absence of reported data means all KPIs for this value are omitted, as per the scoring rules.

Zero Waste & Sustainable Products

The company has implemented two waste reduction initiatives: an average 41% reduction in outbound packaging weight per shipment since 2015, and a policy to ship products in their original packaging to avoid unnecessary additional packaging.

The 41% reduction represents a measurable result from these efforts.